Registry-Based Studies in Practice: Enhancing Real-World Evidence Generation in Rare Disease and Personalized Medicine
Author(s)
Saragoussi D, Rouleau A, Cid Ruzafa J
Evidera, London, UK
Presentation Documents
Objective : The European Medicines Agency (EMA) issued a draft guideline on registry-based studies (RBS) in September 2020. We present our experience designing observational RBS and integrating feed-back received from regulatory authorities. Methods: We reviewed the RBS we designed since September 2020. We summarized their context, objectives, methodological approaches, and EMA feedback received, as applicable. Results: The majority of RBS were observational post-authorisation safety or efficacy studies required in the context of a rare disease or a personalized treatment. We also designed patient registries (PRs) that aim to become data sources for future studies. The two main designs were: 1) prospective cohort studies including sites from the PR; 2) retrospective cohort study using a PR as a secondary data source. In both cases, a key design feature was the availability of key exposure and outcome data in the PR. We encouraged dialogue between the sponsor and existing PRs and occasionally supplemented existing data with new data collection activities (within the PR questionnaire or via additional data collection modules). Most frequently, PRs were few and clearly identified. However, a feasibility assessment was needed in some cases to confirm the availability of key data and models of collaboration. Feed-back from the EMA was favourable for the use of PR (even when not EMA-qualified) as a data source for both prospective and retrospective approaches. Main questions were about the availability and quality of exposure, outcome data and covariates in the PRs and status of the collaboration between the sponsor and the PR. Conclusion: RBS are becoming increasingly used to generate regulatory-grade RWE in Europe. RBS foster academic-industry collaborations, are encouraged by the EMA, and enhance research in the rare disease space that could go beyond regulatory requirements. Early collaboration with PRs facilitates feasibility, data collection and evidence generation planning.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Value in Health, Volume 24, Issue 12, S2 (December 2021)
Code
POSC424
Topic
Clinical Outcomes, Epidemiology & Public Health, Health Policy & Regulatory, Real World Data & Information Systems
Topic Subcategory
Approval & Labeling, Comparative Effectiveness or Efficacy, Health & Insurance Records Systems, Safety & Pharmacoepidemiology
Disease
Multiple Diseases, Personalized and Precision Medicine, Rare and Orphan Diseases